Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use METHYLPHENIDATE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for METHYLPHENIDATE TRANSDERMAL SYSTEM. Methylphenidate Transdermal System, CIIInitial U.S. Approval: 2006
Medication labelWhy this: Advisory · dailymed-prescription
Methylphenidate Transdermal System (methylphenidate transdermal system) is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age. Limitations of Use The use of Methylphenidate Transdermal System is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage [see Warnings and Precautions (5.8), Use in Specific Populations (8.4)].
- generic_name
- methylphenidate
- product_names
- methylphenidate
- ndc
- 0574-2410, 0574-2415, 0574-2420, 0574-2430, 0574-2410-65, 0574-2415-65, 0574-2420-65, 0574-2430-65
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en